Early Postmarket Results with EmboTrap II Stent Retriever for Mechanical Thrombectomy: A Multicenter Experience.


Journal

AJNR. American journal of neuroradiology
ISSN: 1936-959X
Titre abrégé: AJNR Am J Neuroradiol
Pays: United States
ID NLM: 8003708

Informations de publication

Date de publication:
05 2021
Historique:
received: 21 08 2020
accepted: 23 11 2020
pubmed: 13 3 2021
medline: 10 7 2021
entrez: 12 3 2021
Statut: ppublish

Résumé

EmboTrap II is a novel stent retriever with a dual-layer design and distal mesh designed for acute ischemic stroke emergent large-vessel occlusions. We present the first postmarket prospective multicenter experience with the EmboTrap II stent retriever. A prospective registry of patients treated with EmboTrap II at 7 centers following FDA approval was maintained with baseline patient characteristics, treatment details, and clinical/radiographic follow-up. Seventy patients were treated with EmboTrap II (mean age, 69.9 years; 48.6% women). Intravenous thrombolysis was given in 34.3%, and emergent large-vessel occlusions were located in the ICA ( Initial postmarket results with the EmboTrap II stent retriever are favorable and comparable with those of other commercially available stent retrievers. Compared with EmboTrap II, the first-generation EmboTrap may have a higher first-pass efficacy; however, data are limited by retrospective case analysis, incomplete clinical follow-up, and small sample size, necessitating future trials.

Sections du résumé

BACKGROUND AND PURPOSE
EmboTrap II is a novel stent retriever with a dual-layer design and distal mesh designed for acute ischemic stroke emergent large-vessel occlusions. We present the first postmarket prospective multicenter experience with the EmboTrap II stent retriever.
MATERIALS AND METHODS
A prospective registry of patients treated with EmboTrap II at 7 centers following FDA approval was maintained with baseline patient characteristics, treatment details, and clinical/radiographic follow-up.
RESULTS
Seventy patients were treated with EmboTrap II (mean age, 69.9 years; 48.6% women). Intravenous thrombolysis was given in 34.3%, and emergent large-vessel occlusions were located in the ICA (
CONCLUSIONS
Initial postmarket results with the EmboTrap II stent retriever are favorable and comparable with those of other commercially available stent retrievers. Compared with EmboTrap II, the first-generation EmboTrap may have a higher first-pass efficacy; however, data are limited by retrospective case analysis, incomplete clinical follow-up, and small sample size, necessitating future trials.

Identifiants

pubmed: 33707283
pii: ajnr.A7067
doi: 10.3174/ajnr.A7067
pmc: PMC8115375
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

904-909

Informations de copyright

© 2021 by American Journal of Neuroradiology.

Références

N Engl J Med. 2015 Jun 11;372(24):2285-95
pubmed: 25882376
N Engl J Med. 2018 Feb 22;378(8):708-718
pubmed: 29364767
Lancet. 2012 Oct 6;380(9849):1231-40
pubmed: 22932714
Stroke. 2018 May;49(5):1107-1115
pubmed: 29643261
N Engl J Med. 2015 Jan 1;372(1):11-20
pubmed: 25517348
N Engl J Med. 2015 Mar 12;372(11):1019-30
pubmed: 25671798
N Engl J Med. 2015 Mar 12;372(11):1009-18
pubmed: 25671797
J Neurointerv Surg. 2016 Feb;8(2):197-202
pubmed: 25540180
Interv Neuroradiol. 2019 Jun;25(3):271-276
pubmed: 30714502
N Engl J Med. 2018 Jan 4;378(1):11-21
pubmed: 29129157
Interv Neurol. 2017 Oct;6(3-4):268-276
pubmed: 29118805
N Engl J Med. 2015 Jun 11;372(24):2296-306
pubmed: 25882510

Auteurs

A Srivatsan (A)

From the Department of Neurosurgery and Neurology (A.S., V.M.S., Y.S., J.N.J., J.-K.B., P.K.), Baylor College of Medicine, Houston, Texas.

V M Srinivasan (VM)

From the Department of Neurosurgery and Neurology (A.S., V.M.S., Y.S., J.N.J., J.-K.B., P.K.), Baylor College of Medicine, Houston, Texas.

R M Starke (RM)

Department of Neurosurgery (R.M.S., E.C.P., D.R.Y.), University of Miami Miller School of Medicine, Miami, Florida.

E C Peterson (EC)

Department of Neurosurgery (R.M.S., E.C.P., D.R.Y.), University of Miami Miller School of Medicine, Miami, Florida.

D R Yavagal (DR)

Department of Neurosurgery (R.M.S., E.C.P., D.R.Y.), University of Miami Miller School of Medicine, Miami, Florida.

A E Hassan (AE)

Department of Neurology and Radiology (A.E.H.), University of Texas Health Science Center San Antonio, San Antonio, Texas.
Department of Neurology (A.E.H.), University of Texas Rio Grande Valley, Harlingen, Texas.

A Alawieh (A)

Department of Neurosurgery (A.A., A.M.S.), Medical University of South Carolina, Charleston, South Carolina.

A M Spiotta (AM)

Department of Neurosurgery (A.A., A.M.S.), Medical University of South Carolina, Charleston, South Carolina.

Y Saleem (Y)

From the Department of Neurosurgery and Neurology (A.S., V.M.S., Y.S., J.N.J., J.-K.B., P.K.), Baylor College of Medicine, Houston, Texas.

K M Fargen (KM)

Department of Neurosurgery (K.M.F., S.Q.W.), Wake Forest University School of Medicine, Winston-Salem, North Carolina.

S Q Wolfe (SQ)

Department of Neurosurgery (K.M.F., S.Q.W.), Wake Forest University School of Medicine, Winston-Salem, North Carolina.

R A de Leacy (RA)

Department of Neurosurgery (R.A.d.L., I.P.S.), Mt. Sinai Icahn School of Medicine, New York, New York.

I P Singh (IP)

Department of Neurosurgery (R.A.d.L., I.P.S.), Mt. Sinai Icahn School of Medicine, New York, New York.

I L Maier (IL)

Department of Neurology (I.L.M.), University Medical Center Göttingen, Göttingen, Germany.

J N Johnson (JN)

From the Department of Neurosurgery and Neurology (A.S., V.M.S., Y.S., J.N.J., J.-K.B., P.K.), Baylor College of Medicine, Houston, Texas.

J-K Burkhardt (JK)

From the Department of Neurosurgery and Neurology (A.S., V.M.S., Y.S., J.N.J., J.-K.B., P.K.), Baylor College of Medicine, Houston, Texas.

S R Chen (SR)

Department of Interventional Radiology (S.R.C.), MD Anderson Cancer Center, Houston, Texas.

P Kan (P)

From the Department of Neurosurgery and Neurology (A.S., V.M.S., Y.S., J.N.J., J.-K.B., P.K.), Baylor College of Medicine, Houston, Texas ptkan@utmb.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH